Heterotaxia syndromes and 22qll deletion
In a recent issue of your journal we read with interest the very accurate review by Penman Splitt et al' on defects of left-right asymmetry.
The authors correctly reported that in patients with heterotaxia (asplenia and polysplenia syndromes), conotruncal defects are one of the more frequent heart malformations. It is well known that 22q1 1 deletion has been described in a subgroup of patients with conotruncal anomalies in the setting of DiGeorge2" and velocardiofacial syndromes. In the paper of Penman Splitt et all is was reported (personal communication to the authors) that the same microdeletion has been found in two patients, one with dextrocardia and one with left isomerism (polysplenia syndrome).
Since 1993 we have performed clinical and molecular evaluation ofall patients with conotruncal anomalies observed at our hospital,"7 including 20 cases with heterotaxia. Fifteen had asplenia syndrome and five polysplenia. All patients underwent phenotypic and cardiac examinations. Fluorescent in situ hybridisation was used for detecting 22ql 1 deletion.
No patients had phenotypic features of DiGeorge or velocardiofacial syndromes, and the genetic study did not show 22ql 1 deletion in any case. Our experience suggests that the conotruncal anomalies in the setting of heterotaxy syndromes are not related to 22q1 1 deletion, and are probably secondary to distortion of cardiac looping or to the anomaly of the situs itself. Different gene(s) and different developmental mechanisms may be involved in the pathogenesis of conotruncal anomalies in patients with situs solitus and in those with laterality defects. BRUNO This letter was shown to Dr Penman Splitt, who replies as follows.
We entirely agree with Marino et al that the conotruncal anomalies seen in patients with heterotaxy are likely to be secondary to distortion of cardiac looping and thus the mechanism is different from that seen in cases of22ql 1 deletion. Their observations confirm our impression that 22ql 1 deletions are rare in patients with heterotaxy. While the two cases that we referred to are exceptional, they show the extreme phenotypic diversity associated with deletions of 22ql .
First report of three cystic fibrosis patients homozygous for the 1717-1G-A mutation
We report the identification for the first time of three cystic fibrosis (CF) patients homozygous for the 1717-1G-*A' mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
The clinical presentation of CF varies widely, the most common characteristics being chronic obstructive lung disease, raised electrolyte content of sweat, and pancreatic insufficiency (pI).2 About 15% of patients display pancreatic sufficiency (PS).3
The isolation of the CFTR gene' has made it possible to identify the main disease causing mutation, AF508, accounting for about 70% of molecular defects in the world population,4 and over 600 rarer presumptive mutations (CF Genetic Analysis Consortium). Among these, the 1717-1G-*A mutation is a splice site alteration causing a G--A base change at the 3' end of the consensus sequence of intron 10 gically treated with a 10 cm ileal resection. She had a high immune reactive trypsinogen (IRT) value at 5 days of life (173 ng/ml, normal value <40 ng/ml) and CF was confirmed by a positive pilocarpine iontophoresis sweat test (112 mmol/I chloride).9 Global treatment for CF was started at 2 months with pancreatic enzyme supplementation (PancreaseR) and chest physiotherapy (positive expiratory pressure technique). At the latest clinical visit, aged 2 years 4 months, she was normal on examination, weight was 14 kg (75th centile), height 94 cm (97th centile). Good nutritional status was obtained with a low dose of pancreatic enzyme (1785 U/kg/day of pancrelipase) associated with a high fat content diet. A chest x ray showed only minimal thickening of the bronchial walls in the lower lobes. Staphylococcus aureus was intermittently isolated from bronchial secretions. She needed only one therapeutic antibiotic course for upper respiratory tract infection, and had had no admission to hospital since the diagnosis. No alterations in hepatic or nutritional indices were ever noted. Liver ultrasound was in the normal range.
The second patient, case B, a male, was born at term (birth weight 2850 g) to healthy, non-consanguineous parents. CF presented with malabsorption and bronchiolitis, requiring four hospital admissions in the first months oflife. CF was confirmed by a positive pilocarpine iontophoresis sweat test (80, 105 mmol/I chloride). Regular follow up at our specialised CF Centre and adequate treatment were started at 6 months, with pancreatic enzymes (PancreaseR), mucolytic and bronchodilator aerosol, and physiotherapy. He grew impressively after the start oftherapy, body weight reaching the 50th centile at 2 years, and developing along the 97th centile from 5 years. At the last clinical visit, he was asymptomatic, not clubbed, his weight was 38 kg and height 139 cm. Steatorrhoea was absent and fat absorption coefficient was 93%, with 1061 U/kg/day of pancrelipase and a high fat content diet. A chest x ray showed only basal bronchial wall thickening. Sta ' 4 Growth and nutritional status were assessed by anthropometric measures. Pulmonary radiographs were evaluated using the Chrispin and Norman score, ranging from 0 (no damage) to 38 (the worst score). '5 In our group, the severity of pulmonary disease associated with the 1717-1G-+A mutation is highly variable in compound heterozygous patients, but although their mean FVC and FEV1 values are higher than those in AF508 homozygotes, the differences are not statistically significant (table 2) .
The clinical courses of the two CF patients (cases A and B) homozygous for the 1717-1G-A mutation showed that both had early pancreatic involvement and the second an early onset of respiratory symptoms. Conversely, the progression of lung involvement was minimal in both patients, who only require a small amount of therapy. The clinical course is different from that observed in 1717-1G-A/AF508 compound heterozygotes and AF508 homozygotes, even if AF508 homozygotes may exist who display clinical features similar to those of our patients, taking into account their young age.
The general clinical pattern for patient C was slightly more severe than for the other two patients, but the association between GER and acute and chronic respiratory disease in infants and children is well known. In addition, GER has been reported increasingly often in CF and it is known that pulmonary function may be worse in CF patients presenting with GER.'6 Thus, we cannot exclude that in the absence of GER this patient homozygous for the 1717-1G-A mutation might also have developed only a mild lung phenotype.
The data reported here for three 1717-1G-A homozygous patients show an association of early onset ofpulmonary symptoms (two patients) and pancreatic involvement (three patients) with a surprisingly slow progression of pulmonary disease (evident in two patients). Our data suggest that the 1717-1G-A mutation in the homozygous state may be associated with mild to minimal lung disease, even if prediction of slow, mild, progressive pulmonary deterioration in such young CF patients needs further confirmation both in a larger survey and over time when longitudinal data will be available. 1995. ISBN 0-87969-460-2.
As the Editor will attest, it has taken me far too long to find the time to read this book and write the review. In large part, this is because life is far too fraught and hectic for scientists these days to sit back and reflect on the origins and evolution of their subject and the ideas that have shaped it. Yet, ultimately, it was a most rewarding experience to be guided by the deliberately erudite Henry Harris through this fertile terrain which constitutes the still evolving history of somatic cell genetics. After all, I myself had been a participant in some of the crowd scenes, and had met or heard lectures delivered by many of the eminent scientists whose photographs grace the second half of the book, if not their predecessors in the first half. Before somatic cells could be used to explore biology, their credentials had to be painstakingly established. The still continuing elucidation of the role of chromosomes and their constituent DNA in directing cell division and function was begun in the 19th century. Harris cites not only the well known greats like Boveri, but also many less well known figures whose ideas and experiments influenced the star players. The development of cell culture techniques, the inevitable but fateful use of malignant and embryonal cells, improved cytogenetic methodology for visualising chromosomes, the enabling technology of selectable mutant lines which made possible the use of classical complementation techniques, all led eventually to the idea of using these potential tools in more controlled cell fusion experiments. The discovery of interspecific somatic cell hybrids in which species specific chromosome loss (still unexplained) occurs led to the development of the more narrowly defined concept of somatic cell genetics, where parasexual chromosome segregation can be harnessed for the beginnings of gene assignment and mapping. This proved to be a particular bonus for human genetics which had lagged so far behind other organisms where breeding experiments were permissible. Many refinements were introduced, for example, the fragmentation of chromosomes by x irradiation to allow gene order determination (by Steven Goss in Henry Harris's laboratory in the mid 1970s). This approach has recently been revived on a grand scale when development of a combination of automated molecular microtechniques and statistical analysis have made possible the mapping to a very high density of DNA markers, as a prelude to the final human genome sequencing effort which is now in progress.
Gene mapping is only one area revolutionised through the use of somatic cell genetics. Initially, before DNA level analysis by "molecular biology" was made possible through the development of restriction enzymes, Southern blotting, and eventually the polymerase chain reaction (PCR) -each step carefully traced by Harris -all gene mapping was through analysis of express functions. include GenBank accession numbers, which are absent in the previous two chapters. Chapter 4 consists of charts of the major transcription factor families, indicating the relative frequency and importance of specific amino acids at each position. Migraine sufferers would do well to avoid looking at these charts.
The book is full of jargon, much of which is not explained. For example, despite a section of text on UBF, I failed to find out what UBF was an abbreviation of.
It is clear then that this book is intended for transcription factor aficionados with a desire to have a little information on all transcription factors and the references for finding the details they require. For those wishing to know more about transcription factor molecular biology, this book is not for you. The Royal Society philosophical transactions issue on transcription factors would be a better bet.
ROSS HAWKINS

